Foundation Medicine, Inc. (FMI) Files Form 4 Insider Selling : Steven J. Kafka Sells 9,469 Shares

Foundation Medicine, Inc. (FMI): Steven J. Kafka , President & COO of Foundation Medicine, Inc. sold 9,469 shares on Sep 20, 2016. The Insider selling transaction was reported by the company on Sep 22, 2016 to the Securities and Exchange Commission. The shares were sold at $23.70 per share for a total value of $224,415.31 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on Sep 6, 2016, David Daly (Chief Commercial Officer) sold 551 shares at $20.48 per share price.On Aug 23, 2016, Jason Ryan (Chief Financial Officer) sold 13,863 shares at $23.92 per share price.Also, On Aug 9, 2016, Steven J. Kafka (President & COO) sold 10,000 shares at $24.16 per share price.On Jul 6, 2016, Michael J Pellini (Chief Executive Officer) sold 10,160 shares at $17.83 per share price.

Shares of Foundation Medicine Inc (FMI) ended Tuesday, Sep 21, 2016 session in red amid volatile trading. The shares closed down -0.16 points or -0.67% at $23.6 with 1,79,731 shares getting traded. Post opening the session at $23.95, the shares hit an intraday low of $23.43 and an intraday high of $23.98 and the price vacillated in this range throughout the day. The company has a market cap of $824 M and the number of outstanding shares has been calculated to be 3,49,27,435 shares. The 52-week high of Foundation Medicine Inc is $25.31 and the 52-week low is $13.34.

Foundation Medicine Inc Money Flow Index Chart

Foundation Medicine Inc. is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. Its platform includes methods and algorithms for analyzing specimens across various types of cancer and for incorporating that information. Its products provide genomic information about each patient’s individual cancer enabling physicians to optimize treatments in clinical practice and biopharmaceutical companies to develop targeted oncology therapies. Its clinical products FoundationOne for solid tumors and FoundationOne Heme for blood-based cancers or hematologic malignancies including leukemia lymphoma myeloma and various sarcomas and pediatric cancers are available comprehensive genomic profiles designed for use in the routine care of patients with cancer. Its brands also include Once. And for All and The Molecular Information Company.

Leave a Reply

Foundation Medicine Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Foundation Medicine Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.